Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1290)	6/6/2015 8:09:59 AM
From: eico20	Read Replies (1) \| Respond to of 2026

that's correct PR, APRI wanted to sell just EU rights to Femprox and keep USA rights, but the PK studies and the one PH3 trial in EU would have counted towards the 2 PH3's and safety trials needed for the USA approval, I even said to Pascoe, what partner would pay more than half the cost of the USA approval path and not get the rights to the USA as well. Therefore a deal had to be based on Flib. getting USA approval to reduce the risk, since the costs would be great. Unfortunately till now Flib has met alot of delays. Adding to the risk on Femprox is the fact that it's not exactly the same indication, but another drug in a space that hasn't gotten an approval from the FDA , yet. I also agree Actavis with a large female health business would be a great partner for both.